# Sanghoon Park

> Sanghoon Park is co-founder and CEO of Seoul-based Illimis Therapeutics. A POSTECH-trained scientist with a KAIST MBA, he worked in venture investing and executive roles before founding Illimis in 2021. His public interviews emphasize partnerships, employee development, and building an organization able to sustain long-term work.

- **Role:** Co-Founder & CEO at Illimis Therapeutics
- **Organizations:** Illimis Therapeutics, Amyloid Solution, SL BiGen, SL VaxiGen, Partners Investment, Aju IB Investment
- **Education:** Bachelor’s degree in Life Sciences, POSTECH, Master’s degree in Immunology, POSTECH, PhD in Immunology, POSTECH, MBA, KAIST
- **Known for:** Co-founded Illimis Therapeutics in 2021., Led Illimis during its KRW 20 billion Series A and KRW 58 billion Series B financings., Illimis won the 2023 Seoul-BMS Innovation Square Challenge.

## Career timeline

- **2013** — Joined Aju IB Investment; subsequently worked at Partners Investment.
- **Before 2021; exact dates unverified** — Held executive roles at SL BiGen and SL VaxiGen.
- **2017** — Co-founded Amyloid Solution, according to his October 2025 interview.
- **2021** — Co-founded Illimis Therapeutics with scientific co-founders Wonsuk Chung and Chanhyuk Kim.
- **2023** — Illimis announced a KRW 20 billion Series A and won the Seoul-BMS Innovation Square Challenge.
- **2024** — Illimis joined JLABS Singapore and began a Lilly Catalyze360-ExploR&D collaboration.
- **2025** — Illimis announced a KRW 58 billion Series B and a Boston base at Lilly Gateway Labs.

## Achievements

- Co-founded Illimis Therapeutics in 2021.
- Led Illimis during its KRW 20 billion Series A and KRW 58 billion Series B financings.
- Illimis won the 2023 Seoul-BMS Innovation Square Challenge.
- Illimis reported USD 66.4 million in cumulative fundraising as of June 2026.

## Latest updates

- **2026-06** — Illimis’s company overview, last updated June 2026, lists Park as President & CEO and reports USD 66.4 million raised.
- **2026-04** — BIO KOREA 2026’s program lists Park on an April 28 JLABS Korea panel.
- **2025-09** — Illimis announced its Boston presence at Lilly Gateway Labs and Suchul Jang’s appointment to lead its U.S. subsidiary.

## Links

- Website: https://www.illimistx.com/en/
- LinkedIn: https://www.linkedin.com/in/sanghoon-park-bba17051

---

Profile page: https://yespress.io/sanghoon-park
Published by YesPress — https://yespress.io
Last updated: 2026-10-15